Corona Remedies
BSE: CORONA · Pharmaceuticals
Snapshot
Unlock Corona Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Corona Remedies Limited is an Indian pharmaceutical company specialising in chronic and sub-chronic therapeutic segments. It holds a strong position in the domestic market, ranking 27th overall in the Indian Pharmaceutical Market.
Vertical mix
- NaN%
Geography mix
- NaN%
Business Model
The company generates revenue primarily through the sale of pharmaceutical products in domestic and international markets, focusing heavily on specialized therapeutic categories and new product launches.
- Revenue from Operations (FY25-26):1,403.18 crore rupees
- Operating Profit (FY25-26):293.44 crore rupees
Management Commentary
Management highlights robust outperformance relative to the broader market, driven by strong growth in domestic operations and a successful product expansion strategy.
- Domestic Business Growth:17.18%
Growth Outlook
Near-term growth is supported by new product introductions, expansion within high-margin therapeutic portfolios, and outperforming the broader pharmaceutical market rate.
- New Product Contribution:6.39%
- New Products Launched:13
Key Risks
- Regulatory Concentration. Heavy reliance on the domestic market exposes the company to changes in Indian pharmaceutical pricing regulations and government policies.
- Competition. Intense competition within the Indian Pharmaceutical Market could exert pressure on product margins and market share.
- Product Concentration. Significant exposure to chronic therapeutic segments creates vulnerability to shifts in demand or competitive disruption within those specific portfolios.
Start your research today
Unlock AI insights, financials, peers and live data on Corona Remedies and 5,000+ companies — free.
Key Metrics
P/E
64.1×
Q2 FY27 · consolidated
EV/EBITDA
38.2x
Q2 FY27 · consolidated
NET PROFIT MARGIN
13.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Corona RemediesCORONA | ₹13,147 Cr | 64.1× | 38.24 | — | 22.2% | 28.3% | 33.9% | — |
Jubilant Pharmova Ltd.JUBLPHARMA | ₹14,714 Cr | 42.6× | 12.90 | 16.3% | 15.0% | 5.3% | 6.5% | -14.0% |
Marksans Pharma LimitedMARKSANS | ₹13,880 Cr | 27.4× | 16.27 | 57.4% | 25.7% | 31.9% | 39.6% | +71.5% |
Concord Biotech Ltd.CONCORDBIO | ₹13,031 Cr | 43.6× | 28.78 | 4.0% | 38.7% | 14.3% | 18.8% | -19.4% |
Sudeep PharmaSUDEEPPHRM | ₹12,066 Cr | 65.7× | 44.30 | — | 38.8% | 22.4% | 27.7% | — |
Akums Drugs and Pharmaceuticals Ltd.AKUMS | ₹11,517 Cr | 38.5× | 16.00 | 9.2% | 15.6% | 9.2% | 13.8% | +59.1% |
As of Q2 FY27
Financials
Corona Remedies
BSE: CORONA · Pharmaceuticals
Snapshot
Unlock Corona Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Corona Remedies Limited is an Indian pharmaceutical company specialising in chronic and sub-chronic therapeutic segments. It holds a strong position in the domestic market, ranking 27th overall in the Indian Pharmaceutical Market.
Vertical mix
- NaN%
Geography mix
- NaN%
Business Model
The company generates revenue primarily through the sale of pharmaceutical products in domestic and international markets, focusing heavily on specialized therapeutic categories and new product launches.
- Revenue from Operations (FY25-26):1,403.18 crore rupees
- Operating Profit (FY25-26):293.44 crore rupees
Management Commentary
Management highlights robust outperformance relative to the broader market, driven by strong growth in domestic operations and a successful product expansion strategy.
- Domestic Business Growth:17.18%
Growth Outlook
Near-term growth is supported by new product introductions, expansion within high-margin therapeutic portfolios, and outperforming the broader pharmaceutical market rate.
- New Product Contribution:6.39%
- New Products Launched:13
Key Risks
- Regulatory Concentration. Heavy reliance on the domestic market exposes the company to changes in Indian pharmaceutical pricing regulations and government policies.
- Competition. Intense competition within the Indian Pharmaceutical Market could exert pressure on product margins and market share.
- Product Concentration. Significant exposure to chronic therapeutic segments creates vulnerability to shifts in demand or competitive disruption within those specific portfolios.
Start your research today
Unlock AI insights, financials, peers and live data on Corona Remedies and 5,000+ companies — free.
Key Metrics
P/E
64.1x
Q2 FY27 · consolidated
EV/EBITDA
38.2x
Q2 FY27 · consolidated
NET PROFIT MARGIN
13.7%
Q2 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q2 FY27 · consolidated
Peers · Pharmaceuticals
As of Q2 FY27